U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416162) titled 'A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy' on Feb. 11.
Brief Summary: This is a post-marketing surveillance study conducted as part of the Risk Management Plan (RMP) for South Korea, to evaluate the safety and effectiveness of iptacopan in real-world clinical settings for the treatment of either PNH or C3G in Korean patients. Prospective data will be collected from patient medical records to address the objectives for all eligible populations.
Study Start Date: July 31, 2026
Study Type: OBSERVATIONAL
Condition:
Paroxysmal Nocturnal Hemoglobinuria
C3 Glomerulopathy
Recr...